Kathryn Dao, MD
In a video interview, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed:
- recent developments in rheumatoid arthritis treatment, focusing on the major impacts of new guidelines laid out at the recent European Congress of Rheumatology 2022 meeting;
- increased understanding on the major risk factors for patients developing RA, with a focus on environmental risks;
- the impact of depression on RA treatment and quality of life, including the recent revelation that patients with RA who also have depression have a mortality rate six times higher than those without depression
- The current state of JAK inhibitors as a newer development in RA treatment, and her approach towards prescribing them in the face of concerns about side effects;
- concern level around COVID-19 in patients with RA at this stage of the pandemic, and whether or not patients with RA are urged to get fourth and fifth booster shots;
- and interesting new treatments on the horizon for RA, including new JAK inhibitors under development and a “scorpion venom toxin” with potential utility.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.